Pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, Glenmark Pharmaceuticals has informed that a meeting of the Board of Directors will be held on Thursday, November 14, 2024, to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2024. Further, as per the ‘Code of Conduct for Prevention of Insider Trading’ and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its directors and other designated persons regarding the closure of trading window from September 30, 2024 to November 16, 2024 for the purpose of approval of Unaudited Financial Results for the second quarter and half year ended September 30, 2024.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |